Xie Xiaofeng, Ma Mingrui, Bai Xue, Hu Jing, Zheng Haijie, Guo Xiongqi, Huang Jiayi, Chen Xuelian, Chen Liping, Lan Xiaofeng, Song Lin, Du Caiwen
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, P.R. China.
Department of Medical Records, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, P.R. China.
Cancer Control. 2025 Jan-Dec;32:10732748241310578. doi: 10.1177/10732748241310578.
Splenic metastases (SM) from breast cancer (SMBC) are exceedingly rare. To date, the relevant literature is primarily based on pan-tumour species, with only a few studies exploring SM specifically in relation to breast cancer. As such, the present retrospective study explored the clinicopathological characteristics and prognoses of patients with SMBC at the breast care centre of the authors' hospital.
Data from patients newly diagnosed with metastatic breast cancer (MBC) between June 2017 and June 2022 were extracted from medical records at the authors' hospital. Clinicopathological characteristics and their associations with progression-free survival (PFS [time from diagnosis of initial recurrence and/or metastasis to diagnosis of SM]), first overall survival (OS [time from diagnosis of breast cancer to death or last follow-up visit]), and second overall survival (OS [time from diagnosis of SM to death or last follow-up visit]) were analysed in patients with SMBC.
In total, 1009 patients with MBC were identified, of whom 18 (1.7%) had SM. T1 and T2 stages were documented in 15 (83.3%) patients, whereas N2 and N3 were documented in 13 (62.2%). 14 (77.8%) patients were oestrogen receptor and/or progesterone receptor positive. A Ki-67 index ≥ 30% accounted for 72.2% (13/18) of cases, and all patients were histological grade II or III. Liver and/or lung metastases were documented in all 18 (100%) patients. Median PFS was 6.3 months. The median OS and OS were 41.8 and 10.6 months, respectively. The number of previous treatment lines before diagnosis of SM was a significant adverse prognostic factor for PFS, and disease-free survival was a significant adverse prognostic factor for OS.
SMBC commonly presents with diffuse multiple organ metastases in the terminal stage of malignancy and has a poor prognosis, which may provide deeper insight into SMBC for clinicians.
乳腺癌脾转移（SMBC）极为罕见。迄今为止，相关文献主要基于泛肿瘤种类，仅有少数研究专门探讨与乳腺癌相关的脾转移。因此，本回顾性研究在作者所在医院的乳腺护理中心探讨了SMBC患者的临床病理特征及预后。
从作者所在医院的病历中提取2017年6月至2022年6月期间新诊断为转移性乳腺癌（MBC）患者的数据。分析了SMBC患者的临床病理特征及其与无进展生存期（PFS[从初次复发和/或转移诊断至脾转移诊断的时间]）、首次总生存期（OS[从乳腺癌诊断至死亡或最后一次随访的时间]）和第二次总生存期（OS[从脾转移诊断至死亡或最后一次随访的时间]）的关联。
共确定1009例MBC患者，其中18例（1.7%）发生脾转移。15例（83.3%）患者记录为T1和T2期，13例（62.2%）记录为N2和N3期。14例（77.8%）患者雌激素受体和/或孕激素受体阳性。Ki-67指数≥30%的病例占72.2%（13/18），所有患者均为组织学二级或三级。所有18例（100%）患者均记录有肝和/或肺转移。中位PFS为6.3个月。中位OS和第二次OS分别为41.8个月和10.6个月。脾转移诊断前的既往治疗线数是PFS的显著不良预后因素，无病生存期是OS的显著不良预后因素。
SMBC通常在恶性肿瘤晚期表现为弥漫性多器官转移，预后较差，这可能为临床医生深入了解SMBC提供帮助。
